PCSK9 inhibitor therapy

Here’s the quick, practical view. Indications (when to consider adding a PCSK9 inhibitor like evolocumab or alirocumab): - Established ASCVD (prior MI, stroke, PAD) on maximally tolerated statin ± ezetimibe but LDL-C still above goal (generally ≥70 mg/dL; some clinicians use ≥55 mg/dL for very‑high risk per ESC). - Familial hypercholesterolemia (HeFH or HoFH) with high LDL-C despite statin ± ezetimibe, or true statin intolerance with persistently high LDL-C. - Statin intolerance with high ASCVD risk and LDL-C not at goal despite ezetimibe. - Post–acute coronary syndrome needing rapid LDL lowering (add to statin per guideline pathways). - Lp(a) is not an approved indication alone, though PCSK9 inhibitors lower Lp(a) ~20–30%; may sway decisions in very‑high risk patients with high Lp(a) when LDL also needs lowering. Contraindications and key cautions: - Absolute: prior serious hypersensitivity to the drug or its excipients. - Relative/precautions: pregnancy/breastfeeding (limited data—generally avoid), severe hepatic impairment (limited data), children except specialist‑guided FH use, and injection‑site reactions or eosinophilia history with biologics. - Drug interactions: none significant (monoclonal antibodies). However, monitor if used with other potent LDL‑lowering agents for very low LDL; current data show very low LDL is generally safe. - Practical: high cost and need for prior authorization; adherence to injection schedule (every 2 or 4 weeks). Effect sizes and targets: - LDL-C reduction ~50–60% on top of statin; ASCVD event reduction in high‑risk patients (FOURIER, ODYSSEY OUTCOMES). - Typical goals: LDL-C <70 mg/dL for ASCVD; <55 mg/dL for very‑high risk; non‑HDL <100 or <85 mg/dL respectively.